問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of General Surgery

Division of Radiation Therapy

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

劉峻宇Liu, Chun-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

88Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉峻宇

List

171Cases

2020-12-01 - 2025-12-31

Phase I

Completed
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

  • Condition/Disease

    ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

  • Test Drug

    LY3484356

Participate Sites
7Sites

Recruiting7Sites

2025-12-08 - 2032-09-03

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2016-08-01 - 2020-12-31

Phase II

Completed
A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

  • Condition/Disease

    Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer.

  • Test Drug

    Abemaciclib

Participate Sites
7Sites

Terminated6Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2015-07-31 - 2018-07-31

Phase II

Completed
neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer

  • Condition/Disease

    Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer

  • Test Drug

    abemaciclib

Participate Sites
5Sites

Terminated4Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2017-02-01 - 2027-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-03-11 - 2027-03-01

Phase III

Active
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    注射劑

Participate Sites
8Sites

Recruiting8Sites

2018-05-02 - 2022-01-20

Phase III

Completed
A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer

  • Condition/Disease

    HER2-Positive Early Breast Cancer

  • Test Drug

    EG12014

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2024-03-01 - 2028-10-10

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-03-01 - 2024-03-29

Phase I/II

Completed
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Solid Tumor

  • Test Drug

    OBI-3424

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

1 6 7 8 9 10 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB